Exogenous Hormones

La Vecchia C, Altieri A., Franceschi S, Tavani A. Oral contraceptives and cancer. An update. Drug Safety 2001;24:741-54.

IARC. Monographs on the Evaluation of the Carcinogenic Risks to Humans, Vol. 72, Hormonal Contraception and Post-Menopausal Hormonal Therapy. Lyon: International Agency for Research on Cancer, 1999.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347:1713-27.

Moreno V, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, Walboomers JMM, Herrero R, Franceschi S, for the International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papilloma virus infection: the IARC multicentric case-control study. Lancet 2002;359:1085-192.

Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: A meta-analysis. Br J Cancer 2001;84:722-7.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-59.

Magnusson C, Persson I, Adami HO. More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:1183-4.

Bosetti C, Negri E, Franceschi S, Trichopoulos D, Beral V, La Vecchia C. Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 2001; 285: 3089.

Herbert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer among women. Cancer Epidemiol Biomarkers Prev 1998;7:653-9.

Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288: 321-333.

Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D, HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288: 58-66.